Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Non Operating Income (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Non Operating Income for 7 consecutive years, with $853000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Non Operating Income fell 16.29% to $853000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $3.9 million, a 25.02% increase, with the full-year FY2024 number at $3.9 million, up 25.02% from a year prior.
  • Non Operating Income was $853000.0 for Q4 2024 at Actinium Pharmaceuticals, down from $1.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.1 million in Q3 2023 to a low of $35000.0 in Q1 2022.
  • A 4-year average of $516062.5 and a median of $504000.0 in 2023 define the central range for Non Operating Income.
  • Biggest YoY gain for Non Operating Income was 1594.74% in 2022; the steepest drop was 32.69% in 2022.
  • Actinium Pharmaceuticals' Non Operating Income stood at $38000.0 in 2021, then skyrocketed by 1594.74% to $644000.0 in 2022, then skyrocketed by 58.23% to $1.0 million in 2023, then dropped by 16.29% to $853000.0 in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Non Operating Income are $853000.0 (Q4 2024), $1.0 million (Q3 2024), and $1.1 million (Q2 2024).